In conclusion, we identified a new PI3K-δ/PKD signaling pathway that leads to CXCR4/CXCR5 downregulation and is activated upon BCR engagement in CLL progressive cases (Figure 8). This evidence concerns the gene CXCR5 and B-cell chronic lymphocytic leukemia.